Pharmarise Holdings (TSE:2796) Total Operating Expense: 円8,479 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2796 Pharmarise Holdings Corp TSE:2796
50 GF Score
Price 円491.00
GF Value 円608.01
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Pharmarise Holdings Total Operating Expense?

Pharmarise Holdings TSE:2796 -0.61% 50 Total Operating Expense is 円8,479 Mil as of May. 2026. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.01 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Pharmarise Holdings's Total Operating Expense for the six months ended in May. 2026 was 円4,324 Mil. Pharmarise Holdings's Total Operating Expense for the trailing twelve months (TTM) ended in May. 2026 was 円8,479 Mil.

Pharmarise Holdings Total Operating Expense Related Terms

Pharmarise Holdings Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Pharmarise Holdings's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmarise Holdings Total Operating Expense Chart

Pharmarise Holdings Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,596.00 6,695.00 7,533.00 8,671.00 8,479.00

Pharmarise Holdings Semi-Annual Data
Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25 May26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,973.00 4,138.00 4,533.00 4,155.00 4,324.00
TSE:2796
50GF Score
Pharmarise Holdings Corp TSE:2796
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmarise Holdings Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in May. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円8,479 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円8,479 Mil mean?
Pharmarise Holdings (TSE:2796) has a Total Operating Expense of 円8,479 Mil as of May. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pharmarise Holdings and its competitors.
Is Pharmarise Holdings' Total Operating Expense too high?
Pharmarise Holdings' current Total Operating Expense is 円8,479 Mil. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Total Operating Expense compare to competitors?
Pharmarise Holdings' Total Operating Expense of 円8,479 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Healthcare Providers & Services company?
A good Total Operating Expense depends on the Healthcare Providers & Services industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pharmarise Holdings and its competitors. Pharmarise Holdings's current Total Operating Expense is 円8,479 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current Total Operating Expense is 円8,479 Mil. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Total Operating Expense is 円8,479 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued. The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01. GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.

Key valuation signals for TSE:2796:

  • Total Operating Expense: 円8,479 Mil
  • GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
  • GF Score™: 50/100 with 10 warning signs

No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmarise Holdings Business Description

Address 8 Floor, Sumitomo Nakano Sakue Building, 1-38-1 Chuo, Nakano-ku, Tokyo, JPN, 164-0011
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score

Get the complete analysis for TSE:2796

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円491.00
Price
円608.01
GF Value